US5417972A
(en)
*
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
US7935675B1
(en)
*
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
DE19720154A1
(de)
*
|
1997-05-02 |
1998-11-05 |
Max Delbrueck Centrum |
Mittel zur Behandlung von Tumorerkrankungen durch Entfernen von B-Lymphozyten der Patienten
|
US20010033839A1
(en)
*
|
1999-10-04 |
2001-10-25 |
Emilio Barbera-Guillem |
Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
AU1368100A
(en)
*
|
1998-11-19 |
2000-06-13 |
Universite Libre De Bruxelles |
Membrane antigenic structure inducing stoppage of proliferation and apoptosis ofactivated t-lymphocytes
|
EP1637160A3
(en)
*
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
CN101254302B
(zh)
*
|
1999-05-07 |
2011-05-11 |
杰南技术公司 |
使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
|
EP1645292A1
(en)
*
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7074403B1
(en)
*
|
1999-06-09 |
2006-07-11 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
JP2003528805A
(ja)
*
|
1999-07-12 |
2003-09-30 |
ジェネンテック・インコーポレーテッド |
Cd20に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US20020058029A1
(en)
*
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
RS51708B
(sr)
|
2001-05-11 |
2011-10-31 |
Amgen Inc. |
Peptidi i njima srodni molekuli koji se vezuju za tall-1
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
CN102174108B
(zh)
*
|
2002-03-01 |
2016-06-29 |
免疫医疗公司 |
内在化抗-cd74抗体和使用方法
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20090217404A1
(en)
*
|
2002-09-27 |
2009-08-27 |
Lowe Scott W |
Cell-based RNA interference and related methods and compositions
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
US20090186839A1
(en)
*
|
2003-02-17 |
2009-07-23 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in chemoresistance
|
CA2516022C
(en)
*
|
2003-02-17 |
2012-05-29 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in tumor resistance to chemotherapy
|
ES2322267T3
(es)
|
2003-04-09 |
2009-06-18 |
Genentech, Inc. |
Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
KR20060027801A
(ko)
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
B 세포 장애에 대한 조합 요법
|
US20120237441A9
(en)
*
|
2003-11-05 |
2012-09-20 |
Bhat Neelima M |
Enhanced b cell cytotoxicity of cdim binding antibody
|
SG148161A1
(en)
*
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
KR20070029733A
(ko)
|
2004-06-04 |
2007-03-14 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
KR100864549B1
(ko)
|
2004-08-04 |
2008-10-20 |
어플라이드 몰리큘라 에볼류션, 인코포레이티드 |
변이체 fc 영역
|
EP1814913B1
(en)
*
|
2004-11-05 |
2015-08-19 |
IGM Biosciences, Inc. |
Antibody induced cell membrane wounding
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
CN105535967B
(zh)
*
|
2005-02-15 |
2022-05-03 |
杜克大学 |
抗cd19抗体及其在肿瘤学中的应用
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
AU2006244445B2
(en)
*
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
CN101223448B
(zh)
|
2005-05-20 |
2012-01-18 |
健泰科生物技术公司 |
来自自身免疫病受试者的生物学样品的预处理
|
WO2007053184A2
(en)
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
EP1904101A4
(en)
*
|
2005-06-08 |
2011-06-15 |
Univ Duke |
ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
|
UA97469C2
(uk)
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
AU2006272597A1
(en)
|
2005-07-25 |
2007-02-01 |
Emergent Product Development Seattle Llc |
Single dose use of CD20-specific binding molecules
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
EP2066349B1
(en)
|
2006-09-08 |
2012-03-28 |
MedImmune, LLC |
Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
|
LT3597659T
(lt)
|
2007-07-09 |
2023-05-10 |
Genentech, Inc. |
Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
|
AU2008312406B2
(en)
|
2007-10-16 |
2014-03-06 |
Ares Trading S.A. |
Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
MX352922B
(es)
*
|
2009-02-24 |
2017-12-14 |
Esbatech Alcon Biomed Res Unit |
Métodos para identificar inmunoligadores de los antígenos de la superficie celular.
|
SG178358A1
(en)
|
2009-08-11 |
2012-03-29 |
Genentech Inc |
Production of proteins in glutamine-free cell culture media
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
EP2409712A1
(en)
*
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
MX363819B
(es)
*
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
CA2884313C
(en)
|
2012-12-13 |
2023-01-03 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
AU2014367398B2
(en)
*
|
2013-12-17 |
2020-06-18 |
Kling Biotherapeutics B.V. |
Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
PT3303373T
(pt)
|
2015-05-30 |
2020-07-14 |
Molecular Templates Inc |
Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas
|
LT3313879T
(lt)
|
2015-06-24 |
2022-03-25 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš transferino receptorių su pritaikytu giminingumu
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
CN115969970A
(zh)
|
2016-02-10 |
2023-04-18 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan的组合
|
CN109310385A
(zh)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US11043823B2
(en)
*
|
2017-04-06 |
2021-06-22 |
Tesla, Inc. |
System and method for facilitating conditioning and testing of rechargeable battery cells
|